FDA Accepts Exelixis’ NDA for Zanzalintinib Combo in Metastatic Colorectal Cancer
Exelixis Announces FDA Acceptance of New Drug Application for Zanzalintinib Combined with Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Exelixis, Inc. today announced that its New Drug Application (NDA) for…
Bio-Techne Launches Fully Defined Synthetic Solution to Expand 3D Stem Cell and Organoid Culture Portfolio
Bio-Techne Broadens 3D Stem Cell and Organoid Culture Offerings with a Fully Defined, Synthetic Matrix Alternative Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic…
Phase 3 Trial of Fezolinetant in Japan Reports Positive Topline Results for Menopausal Vasomotor Symptoms (VMS)
Phase 3 Trial of Fezolinetant in Japan Reports Positive Topline Results for Menopausal Vasomotor Symptoms (VMS) Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced topline…
EYLEA HD® 8 mg Data at Angiogenesis 2026 Highlight Robust Retinal Disease Profile
EYLEA HD® (aflibercept) 8 mg Data Presented at Angiogenesis 2026 Highlight Robust Clinical Profile in Treating Serious Retinal Diseases Regeneron Pharmaceuticals, Inc. today announced upcoming presentations from its ophthalmology portfolio…
ERLEADA® Shows 51% Lower Mortality vs Darolutamide in mCSPC (Real-World, 24-Month Analysis)
Real-World Head-to-Head Analysis Reveals 51% Lower Risk of Death in Metastatic Castration-Sensitive Prostate Cancer Patients Treated with ERLEADA® (Apalutamide) Compared to Darolutamide—Without Docetaxel—Over 24 Months Johnson & Johnson today announced new…
CagriSema Shows 1.91% HbA1c Drop, 14.2% Weight Loss in REIMAGINE 2 Trial
Novo Nordisk A/S: CagriSema Shows Superior HbA1c Reduction of 1.91% and 14.2% Weight Loss in Adults with Type 2 Diabetes in REIMAGINE 2 Trial Novo Nordisk today announced headline results…
Finerenone Recommended in the EU for Treating Heart Failure Patients with LVEF ≥40%
Finerenone Recommended in the EU for Heart Failure Patients with LVEF ≥40% Bayer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency…
AstraZeneca Expands Weight Management Portfolio via Collaboration with CSPC Pharmaceuticals
AstraZeneca Expands Weight Management Portfolio via Collaboration with CSPC Pharmaceuticals AstraZeneca strengthens its weight management portfolio through a new strategic collaboration agreement with CSPC Pharmaceuticals to advance the development of…
CHMP Grants Positive Opinion for AKEEGA® in BRCA1/2-Mutated mHSPC
Johnson & Johnson Secures CHMP Positive Opinion for AKEEGA®—a Dual-Action Tablet Combining Niraparib and Abiraterone Acetate—for Treating Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Patients with BRCA1/2 Mutations Johnson & Johnson today…
Lilly Chooses Pennsylvania for New Injectable Medicine and Device Manufacturing Facility
Lilly Establishes New Injectable Medicine and Device ManufacturingLilly Chooses Pennsylvania for New Injectable Medicine and Device Manufacturing Facility Eli Lilly and Company today announced plans to invest more than $3.5 billion in…
Glaukos Announces FDA Approval of NDA Supplement Permitting Re-Administration of iDose® TR
Glaukos Announces FDA Approval for Re-Administration of iDose® TR Glaukos Corporation, an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal…
WuXi Biologics and Sinorda Biomedicine Forge Strategic Alliance to Advance Bispecific Antibody Development and Manufacturing
WuXi Biologics and Sinorda Biomedicine Forge Strategic Partnership to Advance Development and Manufacturing of Innovative Bispecific Antibodies WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and…